ProTransit NanoTherapy Overview
Latest Deal Type
Grant
(Announced)
ProTransit NanoTherapy General Information
Description
Provider of a proprietary nanoparticle delivery system intended to treat conditions caused or related to free radical formation. The company's initial system is for skincare, where the application helps to reduce cellular and DNA damage caused by UV exposure, as well as helps to treat acute spinal cord injury, enabling physicians to treat their patients in an enhanced way.
Want to dig into this profile?
We’ll help you find what you need
Learn more
ProTransit NanoTherapy Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 3. Grant |
13-Aug-2018 |
|
00000 |
|
Announced |
Pre-Clinical Trials |
| 2. Grant |
08-Mar-2017 |
00.00 |
00000 |
|
Completed |
Pre-Clinical Trials |
| 1. Early Stage VC (Series A) |
21-Nov-2014 |
$250K |
$250K |
|
Completed |
Pre-Clinical Trials |
ProTransit NanoTherapy Executive Team (2)
| Name |
Title |
Board Seat |
Contact Info |
| Gary Madsen Ph.D |
Co-Founder, President & Chief Executive Officer |
|
|
| Vinod Labhasetwar Ph.D |
Co-Founder |
|
|